source
- Merck and Moderna’s melanoma vaccine shows positive Phase 3 results, boosting investor confidenceMerck and Moderna announced that their personalized melanoma vaccine met the primary endpoint of recurrence‑free survival in a Phase 3 trial when given together with Keytruda. The study showed pati…
- Eli Lilly teams with Amplitude on taRNA vaccine platform as Otsuka ends psychedelic trialEli Lilly announced a collaboration with Amplitude Therapeutics to co‑develop vaccine candidates using a trans‑amplifying RNA (taRNA) platform. The taRNA approach aims to boost antigen expression…